BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15001674)

  • 1. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
    Antoch G; Kanja J; Bauer S; Kuehl H; Renzing-Koehler K; Schuette J; Bockisch A; Debatin JF; Freudenberg LS
    J Nucl Med; 2004 Mar; 45(3):357-65. PubMed ID: 15001674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [FDG-PET and CT in gastrointestinal stromal tumor treated with imatinib].
    Eigtved AI; Berthelsen AK; Kinnander C; Krarup-Hansen A
    Ugeskr Laeger; 2003 Sep; 165(37):3507-9. PubMed ID: 14531350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Reddy MP; Reddy P; Lilien DL
    Clin Nucl Med; 2003 Aug; 28(8):677-9. PubMed ID: 12897659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL; Gietema JA; van der Graaf WT
    Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    Stroobants S; Goeminne J; Seegers M; Dimitrijevic S; Dupont P; Nuyts J; Martens M; van den Borne B; Cole P; Sciot R; Dumez H; Silberman S; Mortelmans L; van Oosterom A
    Eur J Cancer; 2003 Sep; 39(14):2012-20. PubMed ID: 12957455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
    Van den Abbeele AD; Badawi RD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S60-5. PubMed ID: 12528774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
    Gong NJ; Wong CS; Chu YC; Gu J
    NMR Biomed; 2013 Feb; 26(2):185-92. PubMed ID: 22806958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
    Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD
    AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
    Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
    Mabille M; Vanel D; Albiter M; Le Cesne A; Bonvalot S; Le Péchoux C; Terrier P; Shapeero LG; Dromain C
    Eur J Radiol; 2009 Feb; 69(2):204-8. PubMed ID: 19046841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
    Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
    Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
    [No Abstract]   [Full Text] [Related]  

  • 19. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review.
    Treglia G; Mirk P; Stefanelli A; Rufini V; Giordano A; Bonomo L
    Clin Imaging; 2012; 36(3):167-75. PubMed ID: 22542374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
    Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
    Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.